Search Results - "CAVENAGH, J. D"

Adipocytes disrupt the translational programme of acute lymphoblastic leukaemia to favour tumour survival and persistence by Heydt, Q., Xintaropoulou, C., Clear, A., Austin, M., Pislariu, I., Miraki-Moud, F., Cutillas, P., Korfi, K., Calaminici, M., Cawthorn, W., Suchacki, K., Nagano, A., Gribben, J. G., Smith, M., Cavenagh, J. D., Oakervee, H., Castleton, A., Taussig, D., Peck, B., Wilczynska, A., McNaughton, L., Bonnet, D., Mardakheh, F., Patel, B.

“…The specific niche adaptations that facilitate primary disease and Acute Lymphoblastic Leukaemia (ALL) survival after induction chemotherapy remain unclear…”
Get full text

Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study by San-Miguel, J F, Richardson, P G, Sonneveld, P, Schuster, M W, Irwin, D, Stadtmauer, E A, Facon, T, Harousseau, J-L, Ben-Yehuda, D, Lonial, S, Goldschmidt, H, Reece, D, Bladé, J, Boccadoro, M, Cavenagh, J D, Neuwirth, R, Boral, A L, Esseltine, D-L, Anderson, K C

“…Renal impairment is associated with poor prognosis in multiple myeloma (MM). This subgroup analysis of the phase 3 Assessment of Proteasome Inhibition for…”
Get full text

Outcome of second allogeneic transplants using reduced-intensity conditioning following relapse of haematological malignancy after an initial allogeneic transplant by Shaw, B E, Mufti, G J, Mackinnon, S, Cavenagh, J D, Pearce, R M, Towlson, K E, Apperley, J F, Chakraverty, R, Craddock, C F, Kazmi, M A, Littlewood, T J, Milligan, D W, Pagliuca, A, Thomson, K J, Marks, D I, Russell, N H

“…Disease relapse following an allogeneic transplant remains a major cause of treatment failure, often with a poor outcome. Second allogeneic transplant…”
Get full text

Alemtuzumab markedly reduces chronic GVHD without affecting overall survival in reduced-intensity conditioning sibling allo-SCT for adults with AML by Malladi, R K, Peniket, A J, Littlewood, T J, Towlson, K E, Pearce, R, Yin, J, Cavenagh, J D, Craddock, C, Orchard, K H, Olavarria, E, McQuaker, G, Collin, M, Marks, D I

“…By retrospective analysis of 88 patients from the British Society of Blood and Marrow Transplantation registry, we investigated the effect of in vivo T-cell…”
Get full text

Durable Remissions of Myelodysplastic Syndrome and Acute Myeloid Leukemia After Reduced-Intensity Allografting by TAUSSIG, D. C, DAVIES, A. J, CAVENAGH, J. D, OAKERVEE, H, SYNDERCOMBE-COURT, D, KELSEY, S, AMESS, J. A. L, ROHATINER, A. Z. S, LISTER, T. A, BARNETT, M. J

“…To evaluate the use of reduced-intensity (RI) conditioning with allogeneic hematopoietic stem cell transplantation (HSCT) from HLA-identical family donors in…”
Get full text

A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with ⩽30% blasts by Garcia-Manero, G, Sekeres, M A, Egyed, M, Breccia, M, Graux, C, Cavenagh, J D, Salman, H, Illes, A, Fenaux, P, DeAngelo, D J, Stauder, R, Yee, K, Zhu, N, Lee, J-H, Valcarcel, D, MacWhannell, A, Borbenyi, Z, Gazi, L, Acharyya, S, Ide, S, Marker, M, Ottmann, O G

“…Treatment with azacitidine (AZA), a demethylating agent, prolonged overall survival (OS) vs conventional care in patients with higher-risk myelodysplastic…”
Get full text

Incidence and outcome of critical illness amongst hospitalised patients with haematological malignancy: a prospective observational study of ward and intensive care unit based care by Gordon, A. C., Oakervee, H. E., Kaya, B., Thomas, J. M., Barnett, M. J., Rohatiner, A. Z. S., Lister, T. A., Cavenagh, J. D., Hinds, C. J.

“…Summary To determine the incidence and outcome of critical illness amongst the total population of hospital patients with haematological malignancy (including…”
Get full text

Autoimmune cytopenias in the 22q11.2 deletion syndrome by Davies, J. K., Telfer, P., Cavenagh, J. D., Foot, N., Neat, M.

“…Summary We describe two cases of recurrent autoimmune cytopenias, which were subsequently diagnosed with a 22q11.2 deletion/DiGeorge syndrome. The cases are of…”
Get full text

Guillain Barré syndrome precipitated by the use of antilymphocyte globulin in the treatment of severe aplastic anaemia by Kaya, B, Davies, C E, Oakervee, H E, Silver, N C, Gawler, J, Cavenagh, J D

“…This report describes the case of a 54 year old woman with very severe aplastic anaemia who was treated with antilymphocyte globulin (ALG) and developed…”
Get full text

The importance of consistent use of denominators across patient groups in assessing responses in clinical trials by Davies, J. K., Cavenagh, J. D.

Get full text

The anaesthetist's role in acute sickle cell crisis by Vijay, V, Cavenagh, J D, Yate, P

Get full text

Cost-effectiveness of lenalidomide plus dexamethasone vs. bortezomib plus melphalan and prednisone in transplant-ineligible U.S. patients with newly-diagnosed multiple myeloma by Usmani, S Z, Cavenagh, J D, Belch, A R, Hulin, C, Basu, S, White, D, Nooka, A, Ervin-Haynes, A, Yiu, W, Nagarwala, Y, Berger, A, Pelligra, C G, Guo, S, Binder, G, Gibson, C J, Facon, T

“…To conduct a cost-effectiveness assessment of lenalidomide plus dexamethasone (Rd) vs bortezomib plus melphalan and prednisone (VMP) as initial treatment for…”
Get more information

Mullins' syndrome: a new gammopathy-related autoinflammatory syndrome resistant to anakinra by Longhurst, H J, Yong, P F K, Manson, A L, Cavenagh, J D, Grigoriadou, S, Buckland, M S

Get full text

Benign monoclonal expansion of CD8+ lymphocytes in HIV infection by Smith, Penelope R, Cavenagh, Jamie D, Milne, Tim, Howe, Denise, Wilkes, Susanna J, Sinnott, Paul, Forster, Greta E, Helbert, Matthew

“…Background—A transient expansion of the CD8+ T cell pool normally occurs in the early phase of HIV infection. Persistent expansion of this pool is observed in…”
Get full text

Protein A immunoadsorption in chronic refractory ITP reverses increased platelet activation but fails to achieve sustained clinical benefit by CAHILL, M. R, MACEY, M. G, CAVENAGH, J. D, NEWLAND, A. C

“…Adults with chronic relapsing ITP present a difficult therapeutic challenge. The ongoing antibody‐ mediated platelet destruction in this group might be…”
Get full text

Subacute immune response to primary EBV infection leading to post‐transplant lymphoproliferative disease in a renal transplant patient by Leaver, S., Amlot, P., Thuraisingham, R., Norton, A., Aitken, C., Cavenagh, J. D.

“…Summary A 23‐year‐old man sero‐negative for Epstein–Barr virus (EBV) developed recurrent sore throats 3 and 6 months after a renal transplant from an EBV…”
Get full text

Thymic function in adults: evidence derived from immune recovery patterns following myeloablative chemotherapy and stem cell infusion by Cavenagh, J. D., Milne, T. M., Macey, M. G., Newland, A. C.

“…We studied 45 patients aged 14–66 years who had undergone stem cell transplantation for a variety of malignant conditions at least 12 months previously…”
Get full text

Acute myeloid leukaemia blast cells bind to human endothelium in vitro utilizing E-selectin and vascular cell adhesion molecule-1 (VCAM-1) by Cavenagh, J D, Gordon-Smith, E C, Gibson, F M, Gordon, M Y

“…The adhesion of acute myeloid leukaemia (AML) blast cells to human umbilical vein endothelial cells (HUVECs) was investigated in vitro. Adhesion of blast cells…”
Get more information

Autologous transplantation with Philadelphia-negative progenitor cells for patients with chronic myeloid leukaemia (CML) failing to attain a cytogenetic response to alpha interferon by MCBRIDE, N. C, CAVENAGH, J. D, NEWLAND, A. C, LILLINGTON, D. M, MURRELL, C, KELSEY, S. M

“…Between October 1993 and March 1999, 29 patients with CML who were ineligible for allogeneic BMT underwent PBSC harvest using idarubicin, cytarabine and G-CSF…”
Get full text

Successful therapy of transplant-associated veno-occlusive disease with a combination of tissue plasminogen activator and defibrotide by JENNER, M. J, MICALLEF, I. N. M, ROHATINER, A. Z, KELSEY, S. M, NEWLAND, A. C, CAVENAGH, J. D

“…A 36-year-old man underwent matched unrelated donor bone marrow transplantation for chronic myeloid leukaemia. He developed severe hepatic veno-occlusive…”
Get full text